BRIEF-Beam Therapeutics Updates Preclinical Data On Optimized LNP Delivery Approaches · 1m ago
Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data highlighting advancements with the company's approach to developing novel lipid nanoparticle (L...
GlobeNewswire · 27m ago
Beam Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company posted a loss of $58.97 million.
Benzinga · 18h ago
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Sept. 21, 2021: ZM, ROKU, COIN, SGFY, TWOU, DNA, PD, PATH, DDD, KTOS, MKFG, TDOC, HOOD, GENI, VUZI, CND, BEAM, NVTA, PSNL, SLGC, ACHR, BLDE
Zoom Video Communications (ZM) - 99,318 Shares Roku (ROKU) - 83,958 Coinbase Global (COIN) - 108,527 Signify Health (SGFY) - 317,206 2U (TWOU) - 69,969 Ginkgo Bioworks (DNA) - 88,900 PagerDuty (PD) -
Benzinga · 21h ago
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Sept. 17, 2021: PATH, BEAM, NVTA, PD, MKFG, KTOS, HOOD, SE, VUZI, DIS, Z, PSNL
UiPath (PATH) - 74,087  Beam Therapeutics (BEAM) - 8,000  Invitae (NVTA) - 12,198  PagerDuty (PD) - 1,005  Markforged Holding Corp (MKFG) - 216,978  Kratos Defense
Benzinga · 2d ago
Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
Benzinga · 09/15 15:10
Magenta Therapeutics Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study in Q4
MT Newswires · 09/15 09:22
B of A Securities Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $150
B of A Securities analyst Greg Harrison initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $150.
Benzinga · 09/10 16:06
Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a...
GlobeNewswire · 09/08 10:30
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Aug. 20, 2021: FATE, SRNG, BEAM, SGFY, TSP, VCYT, PLTR, AVAV, MKFG, BLDE, SPFR, FTCH, GENI, KVSB, LPSN, SMFR, MASS, RPTX, QSI, ZY, PATH
Fate Therapeutics (FATE) - 397,896 Soaring Eagle Acquisition Corp (SRNG) - 273,629 Beam Therapeutics (BEAM) - 40,061 Signify Health (SGFY) - 18,900 Tusimple Holdings (TSP) - 1,970 Veracyte (VCYT) -
Benzinga · 08/23 14:48
Beam Therapeutics Inc (BEAM) CEO John M. Evans Sold $2 million of Shares
GuruFocus News · 08/21 15:15
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Aug. 17, 2021: PLTR, Z, RPTX, VCYT, QSI, ZY, NTLA, MASS, EDIT, DYNS, CRSP, BLI, SMFR, FATE, EXAS, SGFY, BEAM, NVTA, AVAV, MKFG, BLDE, KMTUY, RBLX, LPSN, KVSB, CND
Palantir Technologies (PLTR) - 476,114 Shares Zillow Group (Z) - 2,800 Repare Therapeutics (RPTX) - 8,967 Veracyte (VCYT) - 40,152 Quantum-Si (QSI) - 163,972 Zymergen (ZY) - 136,853 Intellia Therapeutics (NTLA) -
Benzinga · 08/18 13:25
Brevan Howard Capital Management LP Buys Baidu Inc, Peridot Acquisition Corp, Sells Petroleo ...
GuruFocus News · 08/17 17:38
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why · 08/17 14:21
Farallon Capital Management Llc Buys , ServiceNow Inc, New York Times Co, Sells Alphabet Inc, ,
GuruFocus News · 08/16 07:31
How Are Genomics ETFs Responding to Q2 Earnings? · 08/14 12:00
How Much Of Beam Therapeutics Inc. (NASDAQ:BEAM) Do Insiders Own?
The big shareholder groups in Beam Therapeutics Inc. ( NASDAQ:BEAM ) have power over the company. Institutions will...
Simply Wall St. · 08/14 07:45
Company News for Aug 11, 2021
Companies In The News Are: VSH, SYY, NOVT, BEAM
Zacks · 08/11 13:40
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates · 08/10 11:45
Beam Therapeutics Q2 EPS $(1.23) Down From $(0.69) YoY
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.23) per share. This is a 78.26 percent decrease over losses of $(0.69) per share from the same period last year.
Benzinga · 08/10 10:30
Webull provides a variety of real-time BEAM stock news. You can receive the latest news about BEAM THERAPEUTICS INC. through multiple platforms. This information may help you make smarter investment decisions.
About BEAM
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS). The Company has three development candidates, such as BEAM-101, BEAM-102 and BEAM-201 in which two candidates targeting hemoglobinopathies and one candidate in T-cell therapy program.